

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.

艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

**RESIGNATION OF JOINT COMPANY SECRETARY,
APPOINTMENT OF COMPANY SECRETARY
AND
CHANGE OF AUTHORISED REPRESENTATIVE**

RESIGNATION OF JOINT COMPANY SECRETARY

The board (the “**Board**”) of directors (the “**Directors**”) of AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) hereby announces that Ms. Wong Pui Kiu Ingrid (“**Ms. Wong**”) has tendered her resignation as a joint company secretary of the Company (the “**Joint Company Secretary**”), with effect from December 31, 2025. Ms. Wong confirms that there is no disagreement between herself and the Board and there is no other matter in relation to her resignation that needs to be brought to the attention to the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board wishes to take this opportunity to express its gratitude to Ms. Wong for her contribution during her tenure of office as the Joint Company Secretary.

Ms. Wong will continue to act as the person authorised to accept service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong).

APPOINTMENT OF COMPANY SECRETARY

Ms. Liu Ling (劉靈) (“**Ms. Liu**”), the other Joint Company Secretary, has recently obtained confirmation from the Stock Exchange that, she is qualified to act as the company secretary of the Company under Rule 3.28 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on the Stock Exchange such that a further waiver will not be necessary. Following the resignation of Ms. Wong, Ms. Liu will remain in office and act as the sole company secretary of the Company, with effect from December 31, 2025.

The biographical details of Ms. Liu are set out as follows:

Ms. Liu Ling (劉靈), has served in various management positions since she joined the Company in November 2011 and has served as the secretary to the Board since November 2015 and chief investment officer since March 2022. She is in charge of the general office of the Board and investment management of the Company. Her main responsibilities include such matters as information disclosure, investor relations, equity management and corporate governance of the Company.

Ms. Liu has been the chairwoman of the board of AIM Rongyu (Ningbo) Biopharmaceutical Co., Ltd. (艾美榮譽(寧波)生物製藥有限公司) from December 2019 to June 2021. From February 2014 to January 2019, she was a director of AIM Persistence Biopharmaceutical Co., Ltd. (艾美堅持生物製藥有限公司).

Ms. Liu received her executive master of business administration degree from W.P. Carey in May 2018.

CHANGE OF AUTHORISED REPRESENTATIVE

Following Ms. Wong's resignation as a Joint Company Secretary, she has also resigned as an authorised representative of the Company (the "**Authorised Representative**") as required under Rule 3.05 of the Listing Rules. The Board announces that Ms. Liu has been appointed as the Authorised Representative in replacement of Ms. Wong, with effect from December 31, 2025. Mr. Yan ZHOU (周延), an executive Director, will continue to act as the other Authorised Representative.

By order of the Board
AIM Vaccine Co., Ltd.
Chairman of the Board and CEO
Mr. Yan ZHOU

Beijing, the PRC, December 31, 2025

As at the date of this announcement, the Board comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Shaojun JIA, Mr. Wen GUAN and Mr. Jie ZHOU as executive directors; Mr. Jichen ZHAO as non-executive director; and Professor Ker Wei PEI, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.